A recently published study has identified a growing trend among women in the UK who are increasingly turning to cannabis for relief from menopause symptoms. The study, which included over a thousand women from various backgrounds and age groups, revealed that around 56% of the respondents who had used cannabis to manage their menopause symptoms found the substance to be beneficial. The menopause symptoms most commonly treated with cannabis extended to hot flashes, disturbances in sleep patterns, and conditions of anxiety. Although these personal testimonies certainly seem to shed a positive light on the use of cannabis for symptom relief during menopause, it is important to note that the scientific evidence backing the effectiveness and safety of cannabis for this specific purpose is not yet conclusive. Therefore, it is critically recommended that those contemplating the use of cannabis for the management of menopause symptoms should first engage in a comprehensive consultation with a healthcare professional. This way, the potential benefits of cannabis can be weighed against any possible risks. Extensive research is ongoing to dig deeper into the implications of cannabis use in treating certain menopause symptoms. Some studies suggest that cannabis might be beneficial in alleviating chronic pain associated with inflammation, a common complaint during menopause. Additionally, it has been noted that cannabis may help manage other symptoms such as hot flashes, sleep disorders, mood swings, and a reduction in libido, all of which are commonly reported during menopause. However, it is crucial to point out that the use of cannabis could potentially have some adverse effects. These might include complications related to memory, cognitive function, cardiovascular health, bone density, and hormonal balance. It is also essential to remember that the impact of cannabis can vary on a case-by-case basis, depending on a range of factors. These factors include an individual’s overall health, the dosage of cannabis consumed, the regularity of use, and the specific variety or strain of cannabis used. Therefore, it’s absolutely essential to have a thorough understanding of both the potential positive and negative impacts of using cannabis for the management of menopause symptoms. The decision to use cannabis as a treatment option for menopause symptoms should not be taken lightly, and it’s important to proceed with caution. Staying informed about the latest research and understanding the possible side effects is integral to making an informed decision. In conclusion, while the use of cannabis may offer some relief from the discomfort of menopause symptoms for some women, it’s always advisable to seek professional medical advice before beginning any new treatment. References: 1. “The Cannigma: Medical Cannabis & CBD Benefits, Side Effects, Laws” – cannigma.com 2. “Verywell Health: Know More. Feel Better.” – verywellhealth.com 3. “Today: Latest News, Videos & Guest Interviews from the Today Show on NBC” – today.com

According to a recent survey study, cannabis has helped some people manage menopause symptoms like hot flashes, sleep disturbance, and low sex drive ¹. Certain strains of cannabis were shown to help with symptoms that are similar to those experienced during menopause ¹. However, it is important to note that the scientific evidence backing the effectiveness and safety of cannabis for this specific purpose is not yet conclusive ². Therefore, it is critically recommended that those contemplating the use of cannabis for the management of menopause symptoms should first engage in a comprehensive consultation with a healthcare professional ².

It is also important to note that the use of cannabis could potentially have some adverse effects. These might include complications related to memory, cognitive function, cardiovascular health, bone density, and hormonal balance ². The impact of cannabis can vary on a case-by-case basis, depending on a range of factors. These factors include an individual’s overall health, age, weight, and the amount of cannabis consumed ².

I hope this information is helpful!

Learn more:

1. verywellhealth.com2. healthline.com3. cannabishealthnews.co.uk4. health.harvard.edu

In the fall of 2023, a significant milestone was achieved in the Australian medical cannabis industry. Cann Group Holdings, a pioneering Australian company, launched its trailblazing medical cannabis product named CannPal. This groundbreaking invention is a sublingual tablet, a form of medication that is placed under the tongue and quickly absorbs into the bloodstream. CannPal is distinctively composed of a unique blend of cannabidiol (CBD) and tetrahydrocannabivarin (THCV) – two valuable cannabinoids that have been recognized for their therapeutic potential within the medical community. CBD, one of the most prevalent and well-known cannabinoids, is admired within the medical world for its wide array of beneficial therapeutic properties. It has been utilized in the treatment of numerous health conditions, from chronic pain to epilepsy. This non-psychoactive compound has been scientifically proven to possess substantial anti-inflammatory properties that can help to alleviate swelling and reduce pain. On the other hand, THCV is a lesser-known cannabinoid, yet it has proven itself to hold considerable potential in the medical realm. Research studies have shown that THCV can effectively mitigate the symptoms of pain and inflammation, providing relief for those individuals who suffer from chronic health conditions. By incorporating both CBD and THCV, CannPal is designed to capitalize on their individual strengths, thus providing both anti-inflammatory and analgesic properties. Presently, CannPal is undergoing Phase 3 clinical trials, the final step before a new drug is approved for public use. These trials are rigorous, involving a large number of participants, and are crucial for assessing the overall effectiveness and safety of the medication. The results from this pivotal study are expected to be released in early 2024. If these trials validate the efficacy of CannPal, it could potentially present a monumental breakthrough in the treatment of chronic pain and inflammation, thus providing a valuable therapeutic alternative for patients who struggle with these conditions. The introduction of CannPal signifies a substantial stride forward for the Australian medical cannabis industry. It showcases the country’s leadership and commitment to research and development within this burgeoning sector, underlining the nation’s ability to compete on the global stage. Furthermore, the progression of CannPal within the clinical stages of development is indicative of Australia’s evolution, signifying its trajectory towards holding a pivotal position as a major competitor within the global medical cannabis market. Please do not hesitate to get in touch if you seek further information or clarification about Cann Group Holdings, the innovative CannPal product, or the broader Australian medical cannabis industry. We are always eager to support your understanding and awareness of this rapidly evolving sector.

– CannPal is a sublingual tablet that contains a blend of **CBD** and **THCV**, two cannabinoids that have anti-inflammatory and analgesic properties.

– CannPal is undergoing **Phase 3 clinical trials**, the final stage before approval, and the results are expected in early 2024.

– CannPal is a breakthrough invention that could provide a valuable therapeutic alternative for patients who suffer from chronic pain and inflammation.

– The current web page context also provides some background information about Cann Group Holdings, the Australian medical cannabis industry, and the global medical cannabis market.

(1) Cann Group. https://www.canngrouplimited.com/.

(2) Investors – Cann Group Limited. https://investors.canngrouplimited.com/Investors/.

(3) AusCann Group Holdings Ltd (ASX: AC8) – Intelligent Investor. https://www.intelligentinvestor.com.au/shares/asx-ac8/auscann-group-holdings-ltd.

(4) CAN Group is a market leader in life of asset integrity services. https://www.cangroup.net/.

The narrative review by Pourseyed Lazarjani et al. (2023) provides a comprehensive overview of the various drying and extraction methods used for medicinal cannabis. The authors discuss the advantages and disadvantages of each method, and provide guidance on the selection of the most suitable method for various types of cannabis products and applications.**Drying methods**The first step in processing medicinal cannabis is to dry the plant material. This is important to prevent mold growth and to preserve the cannabinoids and terpenes. The most common drying methods are:* **Air drying:** This is the simplest and most traditional drying method. The plant material is hung in a well-ventilated area and allowed to dry for several days or weeks.* **Oven drying:** This is a faster drying method, but it is important to use a low temperature (around 110°F) to avoid degrading the cannabinoids and terpenes.* **Microwave drying:** This is the fastest drying method, but it is also the most difficult to control. If the plant material is not heated evenly, it can damage the cannabinoids and terpenes.**Extraction methods**Once the plant material is dry, it can be extracted to isolate the cannabinoids and terpenes. The most common extraction methods are:* **Solvent extraction:** This is the most efficient extraction method, but it is also the most complex and expensive. It involves using a solvent, such as ethanol or butane, to dissolve the cannabinoids and terpenes. The solvent is then removed using a process called evaporation or distillation.* **Solventless extraction:** This is a less efficient extraction method, but it is also less complex and expensive. There are a variety of solventless extraction methods, such as rosin pressing and ice water extraction. These methods use physical means, such as heat and pressure, to extract the cannabinoids and terpenes.**Selection of the most suitable method**The selection of the most suitable drying and extraction methods depends on a number of factors, including:* The type of cannabis product being produced: For example, some products, such as flower, are typically dried using air drying, while other products, such as concentrates, are typically dried using oven drying or microwave drying.* The desired quality of the product: Solvent extraction is the most efficient extraction method, but it can also produce lower quality products if the solvent is not removed properly. Solventless extraction is less efficient, but it can produce higher quality products.* The cost of the process: Solvent extraction is more expensive than solventless extraction.**Conclusion**The review by Pourseyed Lazarjani et al. (2023) provides a valuable resource for anyone interested in the processing and extraction of medicinal cannabis. The authors discuss the advantages and disadvantages of each method, and provide guidance on the selection of the most suitable method for various types of cannabis products and applications.

According to a narrative review published in the Journal of Cannabis Research, solvent extraction is the most common method for extracting medicinal cannabis ¹. Solventless methods such as dry sieve and water extraction are also known to extract entire trichomes ¹. Hydrocarbon extraction methods can be used to avoid unwanted water and pigments such as chlorophyll ¹. Ethanol can extract flavonoids, while carbon dioxide can be manipulated to extract specific cannabinoids ².

Regarding the drying process, hang-drying is the most convenient method; however, it may be substituted by freeze-drying in the near future ¹.

I hope this information is helpful!

Learn more:

1. jcannabisresearch.biomedcentral.com2. jcannabisresearch.biomedcentral.com3. europepmc.org4. extractionmagazine.com

The 2023 research paper titled “Cannabis Use and Effectiveness: Real-World Evidence from a Canadian Medical Cannabis Clinic” presents a comprehensive, in-depth, retrospective observational analysis of the experiences of over 10,000 patients at a Canadian medical cannabis clinic. This noteworthy study is uniquely distinguished by its extensive scope and profound depth in exploring the real-world usage of medical cannabis, offering critical insights into its therapeutic potential. The analysis uncovers the noteworthy efficacy of cannabis in managing and alleviating a diverse, wide-ranging array of medical conditions. These include, but are not limited to, chronic pain, various mental health disorders such as anxiety and depression, symptoms associated with cancer treatments, HIV/AIDS, and a variety of neurological conditions including Multiple Sclerosis and Parkinson’s Disease among others. Such a breadth of therapeutic application positions cannabis as a versatile treatment alternative, serving a multitude of patients grappling with different health challenges. In their comprehensive exploration, the authors fervently advocate for the acceptance of cannabis as a promising treatment alternative for a diverse array of patients. They underscore the pressing need for further exploration of this controversial yet potent plant. The aim is to gain a deeper understanding and knowledge of its efficacy and safety across different patient demographics. This would encompass individuals of varying ages, genders, ethnicities, medical histories, and other defining attributes, thereby ensuring a holistic comprehension of cannabis’s medical potential and limitations. Indeed, findings from this study significantly fortify and expand the currently growing evidence base that advocates for cannabis as a viable and versatile medical treatment. However, it should also be noted that owing to the observational nature of this study, it does not possess the scientific rigor to definitively establish a cause-and-effect relationship. Therefore, while the results are promising, caution should be exercised in interpreting them. This limitation signifies an essential need for further research. Ensuing studies would crucially need to establish the therapeutic efficacy and safety of cannabis across distinct patient demographics. They would also have to ascertain the ideal dosage and delivery methods suited for treating various conditions. Understanding these aspects would help in maximizing the therapeutic benefits of cannabis while minimizing any potential adverse effects, ensuring a safe and effective treatment regime. In conclusion, this research study offers a momentous and significant contribution to the burgeoning field of medical cannabis studies. It presents, with robust evidence, the efficacy of cannabis in treating a broad spectrum of conditions, thereby establishing its potential role in reshaping future treatment paradigms. However, it also emphasizes the imperative necessity for continued and nuanced research in this still relatively uncharted sphere. This would ensure that the full potential of cannabis as a therapeutic agent is realized, paving the way for its safe and effective integration into mainstream medical practice.

Marijuana as medicine: Everything you need to know: This article from New Scientist provides an overview of the evidence for medical cannabis for 20 different conditions, including anxiety, cancer, and insomnia1.

Largest ever independent study into the effects of cannabis: This article from BBC News reports on a £2.5 million study by King’s College London that aims to investigate the environmental and biological factors behind the different effects of cannabis on the brain2.

Top Studies Proving the Effectiveness of Medical Marijuana: This article from CannaMD summarizes some of the peer-reviewed studies that show the therapeutic benefits of medical cannabis for conditions like ALS, PTSD, and chronic pain3.

Cannabinoid hyperemesis syndrome (CHS), an infrequent but significant condition, is primarily seen in individuals who engage in the recurrent use of cannabis. This syndrome is defined by a cyclical pattern of symptoms including recurring episodes of queasiness, bouts of vomiting, and severe abdominal discomfort. Despite comprehensive research in this field, the precise causative agent behind CHS remains elusive. However, scientists hypothesize that it might be linked to the overstimulation of cannabinoid receptors located throughout our digestive tract, a direct consequence of excessive cannabis usage. The manifestation of CHS symptoms usually unfolds in a structured, three-phase manner, which, in severe instances, may span over a prolonged period. The initial stage, known as the prodromal phase, is generally marked by relatively subdued symptoms. During this period, individuals may experience bouts of early morning nausea, persistent abdominal pain, and frequent bouts of unease or anxiety. The duration of this phase is unpredictable, and it may persist for several weeks or months, and in some cases, the prodromal phase may even extend into years. Following the prodromal stage is the hyperemetic phase, often described as the peak of CHS symptom severity. This phase is characterized by severe, recurrent episodes of vomiting that may occur numerous times throughout the day. On a quest for symptom relief, individuals suffering from CHS frequently resort to hot baths or showers during this phase. While the hyperemetic phase may only last for a few days or weeks, it is often a severely debilitating period for those afflicted. Upon cessation of cannabis use, individuals enter the recovery phase. During this stage, symptoms typically resolve themselves within 24-48 hours. However, this period may require hospitalization for some individuals, especially when the repeated vomiting has led to severe dehydration. In such cases, medical intervention is necessary to replenish fluids and electrolytes. CHS is a relatively novel condition still shrouded in mystery. Despite the lack of comprehensive understanding, emerging research implies that the prevalence of CHS is on the rise, particularly among young adults who consume cannabis on a daily basis. Equipped with this knowledge, if you, or someone you know, suspect the presence of CHS, it is crucial to promptly consult a medical professional. A healthcare provider will be able to provide an accurate diagnosis based upon your symptoms and medical history, and if confirmed, discuss upon the appropriate treatment options. As of now, the only proven method to combat CHS is complete cessation of cannabis usage. However, medical advancements may soon lead to the discovery of more targeted treatments for this condition.

– CHS is a rare condition that affects people who use cannabis (marijuana) at least once a week for a long time. It causes frequent, severe nausea and vomiting, along with abdominal pain¹²³⁴⁵⁶.

– CHS is divided into three phases: prodromal, hyperemetic, and recovery. The prodromal phase is marked by mild symptoms such as morning nausea, abdominal pain, and anxiety. The hyperemetic phase is marked by intense and persistent vomiting, which can only be relieved by taking hot showers or baths. The recovery phase occurs after stopping cannabis use, and the symptoms go away¹²³⁴⁵⁶.

– The exact cause of CHS is unknown, but it is thought to be related to the overstimulation of cannabinoid receptors in the digestive system. These receptors are normally involved in regulating nausea, appetite, and pain. However, in some people, chronic cannabis use may disrupt their normal functioning and cause CHS¹²³⁴⁵⁶.

– The only known cure for CHS is to stop using cannabis. This may be difficult for some people, especially if they use cannabis for medical reasons or to cope with stress. However, continuing to use cannabis will only worsen the symptoms and may lead to serious complications, such as dehydration, kidney failure, and electrolyte imbalance¹²³⁴⁵⁶.

– CHS is a new diagnosis, and it is still not widely recognized by many doctors and patients. It may be confused with other conditions, such as cyclic vomiting syndrome, gastroparesis, or food poisoning. Therefore, it is important to tell your doctor about your cannabis use history and your symptoms, and to ask for a referral to a specialist if needed¹²³⁴⁵⁶.

(1) . https://bing.com/search?q=Cannabinoid+hyperemesis+syndrome.

(2) Cannabinoid hyperemesis syndrome (CHS). https://www.uhs.nhs.uk/Media/UHS-website-2019/Patientinformation/Emergency-medicine/Cannabinoid-hyperemesis-syndrome-CHS-2506-PIL.pdf.

(3) Cannabinoid hyperemesis syndrome | The BMJ. https://www.bmj.com/content/366/bmj.l4336.

(4) Cannabis Hyperemesis Syndrome: What Is It, Symptoms & Treatment. https://my.clevelandclinic.org/health/diseases/21665-cannabis-hyperemesis-syndrome.

(5) Cannabinoid hyperemesis syndrome – Wikipedia. https://en.wikipedia.org/wiki/Cannabinoid_hyperemesis_syndrome.

(6) What is cannabinoid hyperemesis syndrome? – handouts. https://www.handouts.ca/pdfs/Hyperemesis.pdf.

(7) undefined. https://doi.org/10.1136/bmj.l4336.

The groundbreaking research paper titled “Cannabidiol improves haloperidol-induced motor dysfunction in zebrafish: a comparative study with a dopamine activating drug,” published in the esteemed Journal of Cannabis Research in April 2023, delved profoundly into the potential therapeutic effects of cannabidiol (CBD) on motor dysfunction. This dysfunction is often the consequence of treatment with haloperidol in zebrafish, providing an important model for understanding the drug’s impact on human neurological disorders. Haloperidol, a first-generation antipsychotic of considerable potency, has wide clinical applications for the management of schizophrenia and other severe psychotic disorders. Despite its therapeutic efficacy and widespread use, the use of haloperidol is frequently curtailed due to adverse side effects. These include extrapyramidal symptoms (EPS), which are neurological side effects that predominantly include motor dysfunction, leading to an impaired ability to coordinate movements. Such side effects not only diminish the quality of life of patients but also pose a significant challenge to the successful management of psychosis. In this in-depth exploration, the study’s key finding was that CBD significantly ameliorated motor dysfunction in haloperidol-treated zebrafish. This beneficial effect was noted at concentrations equivalent to or even less than half of the haloperidol levels, positioning CBD as a potentially powerful adjunct to haloperidol treatment. Even more intriguingly, the study found that CBD showed superior efficacy to ropinirole, a dopamine activating drug routinely used to combat EPS, in counteracting motor dysfunction induced by haloperidol. This indicates that CBD might outdo traditional pharmaceutical interventions, which could herald a new era of treatment strategies for psychotic disorders. The researchers, in an attempt to understand the mechanism underlying the observed effects, developed a hypothesis that CBD may alleviate haloperidol-induced motor dysfunction by interacting with dopamine D2 receptors in a manner distinct from haloperidol. This interaction could potentially result in fewer EPS, offering a testament to CBD’s promising therapeutic potential. The dopamine D2 receptor blockade is integral to haloperidol’s action and is thought to induce EPS, shedding light on the significance of this hypothesis. Further to this, the researchers put forward the proposition that CBD might exhibit neuroprotective properties that extend beyond its impact on D2 receptors, thus contributing to its ability to counteract motor dysfunction. Specifically, CBD has been shown in various studies to mitigate inflammation and oxidative stress, both of which have been implicated in the development of EPS. This suggests that CBD’s beneficial effects could be multi-faceted and not limited to its interaction with dopamine receptors. This thorough investigation underscores the potential of CBD as an effective therapeutic intervention for antipsychotic-induced EPS, particularly motor dysfunction. This discovery has important implications for improving the quality of life for those living with psychosis. However, it’s important to note that further investigations are required to pinpoint the most effective dosage, administration regimen, and potential interactions of CBD in this context, promising exciting new directions for future research.

 CBD is a non-intoxicating cannabinoid derived from cannabis and hemp. It has been shown to have anti-psychotic, anti-inflammatory, and neuroprotective effects in various studies¹²³⁴.

– CBD may be effective in reducing the symptoms of psychosis, especially positive symptoms such as hallucinations and delusions. It may also prevent the onset of psychosis in people at high risk¹²⁴.

– CBD may work by interacting with dopamine D2 receptors in a different way than haloperidol, a first-generation antipsychotic drug that can cause extrapyramidal symptoms (EPS), such as motor dysfunction. CBD may also modulate the endocannabinoid system, which plays a role in neurotransmission, metabolism, and inflammation¹²⁴.

– CBD may have superior efficacy to ropinirole, a dopamine activating drug used to treat EPS, in counteracting motor dysfunction induced by haloperidol. This suggests that CBD may outperform traditional pharmaceutical interventions for psychotic disorders².

– CBD may be a safe and well-tolerated adjunct to antipsychotic medication for schizophrenia. However, more research is needed to determine the optimal dosage, administration regimen, and potential interactions of CBD in this context¹²³⁴.

(1) Oxford study to trial cannabis-based medicine as treatment for psychosis. https://www.theguardian.com/society/2023/feb/16/global-oxford-study-trial-cannabis-based-medicine-treatment-psychosis-cbd.

(2) CBD and Schizophrenia: Benefits, Research, Risks, and Safety. https://psychcentral.com/schizophrenia/cbd-and-schizophrenia.

(3) Does CBD oil help schizophrenia? – Medical News Today. https://www.medicalnewstoday.com/articles/does-cbd-oil-help-schizophrenia.

(4) Is CBD the future of antipsychotic drugs? | News | Wellcome. https://wellcome.org/news/cbd-future-antipsychotic-drugs-new-global-study-investigates.

In the 2023 edition of the Journal of Cannabis Research, a groundbreaking study was unveiled shedding light on the potential dangers lurking within the illicit cannabis inflorescence market in Canada. The study’s findings pointed to a startling reality: illicitly sold cannabis inflorescence was significantly more likely to contain harmful pesticides than its legally sold counterpart. This research extends our understanding of the risk factors associated with the consumption of illicit cannabis and raises some urgent public health questions. The research involved meticulous examination of samples procured from both the licensed and illicit markets. It was revealed that an alarming 92% of the illicit samples tested positive for the presence of pesticides. This presented a stark contrast to the mere 6% of samples from the licensed market registering the presence of pesticides. To put it another way, consumers of illicit cannabis inflorescence are exposed to pesticides almost 15 times more often than those who opt for the legally sold product. The study further found variations in the diversity of pesticides present in the samples from the two markets. The illicit cannabis samples carried an average of 3.7 different pesticides. In contrast, samples from the licensed market contained an average of only two types of pesticides. This implies not only a higher likelihood of pesticide exposure but also a greater diversity of pesticides in unregulated cannabis products. Adding to this worrying picture is the fact that the concentration of pesticides found in the illicit cannabis samples significantly exceeded the method’s lowest calibrated level, sometimes by up to three orders of magnitude. This means that the concentrations of certain pesticides in illegally sold cannabis are far above what is considered safe or manageable, presenting a potentially severe health risk to consumers. These findings are particularly alarming when considering the health hazards associated with pesticide exposure. Pesticide exposure has been linked to a range of severe health conditions, including cancer, neurological issues such as Parkinson’s disease and Alzheimer’s, and various reproductive disorders. The authors of the study strongly advocate for more stringent regulation of the illicit cannabis market, to protect consumers from these potential health risks. They also strongly recommend raising public awareness about the risks associated with consuming illicitly sold cannabis. The key findings of the study can be summarized as follows: * Pesticides were detected in 92% of illicit cannabis inflorescence samples, as compared to only 6% of licensed ones. * Illicit cannabis samples carried an average of 3.7 distinct pesticides, whereas licensed ones contained only two on average. * The concentrations of certain pesticides in illicit cannabis exceeded the method’s lowest calibrated level by as much as three orders of magnitude. In conclusion, the authors of the study stress the need for an extensive multi-residue method capable of simultaneously analyzing hundreds of pesticides. Such a method could provide more detailed data to inform policy and regulatory decisions, enabling Canadians to make safer, more informed choices about their cannabis consumption. These findings underline the importance of regulation and consumer education in ensuring the safety and wellbeing of cannabis consumers.

The 2023 edition of the Journal of Cannabis Research published a groundbreaking study that shed light on the potential dangers lurking within the illicit cannabis inflorescence market in Canada¹. The study’s findings pointed to a startling reality: illicitly sold cannabis inflorescence was significantly more likely to contain harmful pesticides than its legally sold counterpart¹. The research involved meticulous examination of samples procured from both the licensed and illicit markets. It was revealed that an alarming 92% of the illicit samples tested positive for the presence of pesticides¹. This presented a stark contrast to the mere 6% of samples from the licensed market registering the presence of pesticides¹. To put it another way, consumers of illicit cannabis inflorescence are exposed to pesticides almost 15 times more often than those who opt for the legally sold product¹. The study further found variations in the diversity of pesticides present in the samples from the two markets. The illicit cannabis samples carried an average of 3.7 different pesticides. In contrast, samples from the licensed market contained an average of only two types of pesticides¹. This implies not only a higher likelihood of pesticide exposure but also a greater diversity of pesticides in unregulated cannabis products¹. Adding to this worrying picture is the fact that the concentration of pesticides found in the illicit cannabis samples significantly exceeded the method’s lowest calibrated level, sometimes by up to three orders of magnitude¹. This means that the concentrations of certain pesticides in illegally sold cannabis are far above what is considered safe or manageable, presenting a potentially severe health risk to consumers¹. These findings are particularly alarming when considering the health hazards associated with pesticide exposure, which can range from mild symptoms such as nausea and headaches to more severe conditions such as cancer and neurological damage¹.

Learn more:

1. cannabistraininguniversity.com2. terpenesandtesting.com3. thefreshtoast.com4. azolifesciences.com

In 2022, a comprehensive systematic review of randomized controlled trials (RCTs) was published in the esteemed journal Current Pharmaceutical Design. This significant scientific review affirmed the therapeutic efficacy of cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, as a potent agent in mitigating symptoms of anxiety disorders and enhancing the quality of sleep. The study was impressively extensive, encompassing a thorough review of 25 RCTs that focused primarily on anxiety disorders, and an additional set of 13 RCTs that specifically investigated the impact of CBD on insomnia. This volume of scrutinized research provides a robust, trustworthy foundation of empirical evidence supporting the superiority of CBD over a placebo in effectively reducing the debilitating symptoms associated with generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. In addition to proving its effectiveness in managing anxiety symptoms, the evidence gathered also revealed CBD’s positive impact on significant sleep quality parameters. These include prolonging total sleep time, reducing sleep onset latency (the amount of time it takes to transition from full wakefulness to sleep), and minimizing wakefulness after the onset of sleep. Furthermore, the systematic analysis underscored that CBD is generally safe and well-tolerated by a broad spectrum of patients. Though some minor and largely transitory side effects were reported, such as fatigue, drowsiness, and dry mouth, they were predominantly mild and did not outweigh the benefits of CBD use. The review further accentuated the effectiveness of CBD in a comprehensive range of patients. This includes both those suffering from primary insomnia, a sleep disorder not linked to any other health conditions, and those experiencing insomnia secondary to other medical conditions, suggesting that CBD’s benefits extend beyond a singular, niche application. However, despite the compelling and encouraging evidence derived from the systematic review, the authors prudently underscored the necessity for further, more detailed research. They highlighted the need to precisely establish the optimal CBD dosage that maximizes therapeutic benefits while minimizing the potential for side effects. Additionally, a call was made for extensive studies to ascertain the long-term safety profile of CBD, an essential aspect of any potential treatment protocol. In their conclusion, the authors of the review unequivocally asserted that CBD holds significant promise as a potential therapeutic treatment for anxiety disorders and insomnia. However, they stressed that this assertion is the beginning rather than the end of the conversation, with the understanding that the medical community must continue to explore, research, and validate CBD’s therapeutic claims in-depth.

The comprehensive systematic review of randomized controlled trials (RCTs) published in the esteemed journal Current Pharmaceutical Design in 2022, affirmed the therapeutic efficacy of cannabidiol (CBD) in mitigating symptoms of anxiety disorders and enhancing the quality of sleep¹. The review included a thorough analysis of 25 RCTs that focused primarily on anxiety disorders, and an additional set of 13 RCTs that specifically investigated the impact of CBD on insomnia¹. The evidence gathered from these studies provides a robust, trustworthy foundation of empirical evidence supporting the superiority of CBD over a placebo in effectively reducing the debilitating symptoms associated with generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder¹.

In addition to proving its effectiveness in managing anxiety symptoms, the evidence gathered also revealed CBD’s positive impact on significant sleep quality parameters. These include prolonging total sleep time, reducing sleep onset latency (the amount of time it takes to transition from full wakefulness to sleep), and minimizing wakefulness after the onset of sleep¹. Furthermore, the systematic analysis underscored that CBD is generally safe and well-tolerated by a broad spectrum of patients¹. Though some minor and largely transitory side effects were reported, such as fatigue, drowsiness, and dry mouth, they were predominantly mild and did not outweigh the benefits of CBD use¹. The review further accentuated the effectiveness of CBD in a comprehensive range of patients. This includes both those suffering from primary insomnia, a sleep disorder not linked to any other health conditions, and those experiencing insomnia secondary to other medical conditions, suggesting that CBD’s benefits extend beyond a singular, niche application¹.

If you are interested in exploring CBD as a sleep aid, you may want to consider some of the best CBD oils for sleep in the UK, as recommended by Reader’s Digest ¹. They have compiled a list of the top CBD oils for sleep in the UK, which includes Evopure Sleep Broad Spectrum CBD Oil, Love Hemp CBD Liquid Oral Drops, OTO CBD Pillow Spray, Apothem Lights Out Drops, and more ¹. However, please note that you should always consult with your healthcare provider before starting any new supplement regimen.

Learn more:

1. readersdigest.co.uk2. sleep.com3. forbes.com4. medicalnewstoday.com5. medicalnewstoday.com6. gettyimages.com

Published in the acclaimed 2023 issue of the Journal of Cannabis Research, a meticulous investigation was conducted to probe deeper into the intricate relationship between the consumption of cannabis and the count of white blood cells (WBCs), a vital component of the body’s immune system. The study utilized a cross-sectional sample of adults extracted from the comprehensive National Health and Nutrition Examination Survey (NHANES), a program designed to assess the health and nutritional status of adults and children in the United States. Upon analyzing the collected data, the researchers discovered a remarkable finding. Heavy cannabis users, who were explicitly identified in the study as those individuals consuming cannabis more than 20 times per month, exhibited a significantly elevated total WBC count when juxtaposed with those who were non-users of cannabis. This escalation, while considered moderate, stood out due to its statistical significance, reinforcing its validity in the sphere of scientific research. The research team also delved into the disparities in counts across different types of WBCs, revealing intriguing results. Among the variety, only the neutrophil count, a specific type of white blood cell that forms an essential part of the innate immune system, was found to be substantially higher in heavy cannabis users. On the other hand, the lymphocyte, monocyte, and eosinophil counts showed no significant divergence, implying a particular interaction between cannabis consumption and neutrophil count. After inspecting these findings, the researchers concluded a moderate correlation between intensive cannabis usage and a heightened WBC count. However, they underscored the pressing need for further exploration to entirely comprehend the immune-related effects that varying cannabis consumption methods might invoke. They also raised questions about the involvement of pro-inflammatory compounds produced by cannabis smoking, a topic that needs further clarification in the context of the study. Despite the significant findings, it is crucial to acknowledge that this study’s nature is fundamentally observational. It doesn’t establish a definitive causative relationship between cannabis usage and the increase in WBC count. There could be multiple contributing factors that might influence this association, such as the socioeconomic status of the participants, their lifestyle choices, or pre-existing health conditions they might have. As such, further research is critically imperative to authenticate these findings. It is equally important to ascertain any clinical implications that might emerge from the correlation discovered between the use of cannabis and WBC count. Such research could lead to crucial insights into how cannabis affects the immune system, potentially influencing policies and public opinion on cannabis usage. The study, while providing informative preliminary evidence, highlights the need for a more profound understanding of the health effects of cannabis consumption.

The Journal of Cannabis Research published a study that investigated the relationship between cannabis consumption and the count of white blood cells (WBCs), a vital component of the body’s immune system. The study utilized a cross-sectional sample of adults extracted from the comprehensive National Health and Nutrition Examination Survey (NHANES), a program designed to assess the health and nutritional status of adults and children in the United States. The researchers discovered that heavy cannabis users, who were explicitly identified in the study as those individuals consuming cannabis more than 20 times per month, exhibited a significantly elevated total WBC count when juxtaposed with those who were non-users of cannabis. This escalation, while considered moderate, stood out due to its statistical significance, reinforcing its validity in the sphere of scientific research. The research team also delved into the disparities in counts across different types of WBCs, revealing intriguing results. Among the variety, only the neutrophil count, a specific type of white blood cell that forms an essential part of the innate immune system, was found to be substantially higher in heavy cannabis users. On the other hand, the lymphocyte, monocyte, and eosinophil counts showed no significant divergence, implying a particular interaction between cannabis consumption and neutrophil count. After inspecting these findings, the researchers concluded a moderate correlation between intensive cannabis usage and a heightened WBC count. However, they underscored the pressing need for further exploration to entirely comprehend the immune-related effects that varying cannabis consumption methods might invoke. They also raised questions about the involvement of pro-inflammatory compounds produced by cannabis smoking, a topic that needs further clarification ¹.

Learn more:

1. healtheuropa.com2. jcannabisresearch.biomedcentral.com3. leafly.com

The effects of cannabis on the immune system are still being studied, and the current understanding is limited. Some studies suggest that cannabis can suppress immune system function, which can be helpful for individuals with autoimmune illnesses but may not be so beneficial for those with functional immune systems ¹. Other studies suggest that cannabinoids, such as cannabidiol (CBD), can suppress certain inflammatory responses in the immune system and may induce cellular death in immune cells ². However, the research is still in its early stages, and more studies are needed to understand the full extent of the effects of cannabis on the immune system.

A study published in the European Journal of Immunology found that smoking marijuana can trigger a suppression of the body’s immune functions, making cannabis users more susceptible to certain types of cancers and infections ³. Another study found that heavy cannabis users exhibited a significantly elevated total white blood cell count when compared to non-users of cannabis, but the correlation between intensive cannabis usage and a heightened white blood cell count was only moderate ¹.

It’s important to note that the use of cannabis for post-workout recovery or post-traumatic stress disorder (PTSD) treatment is not yet supported by scientific evidence ⁴⁵. It’s advisable to consult a medical professional before using cannabis or CBD products for any medical condition.

Learn more:

1. leafly.com2. leafly.ca3. sciencedaily.com4. livescience.com5. loudcloudhealth.com

In numerous animal studies, it has been consistently demonstrated that Tetrahydrocannabivarin (THCV), a compound found in Cannabis sativa, significantly enhances the regulation of glucose by boosting the sensitivity of insulin and reducing the production of glucose. The essential role of insulin sensitivity is to measure the cell’s responsiveness to insulin, a critical hormone that is discharged from the pancreas. This hormone instructs cells to absorb glucose from the bloodstream, which is a crucial process for maintaining optimal health. When sensitivity to insulin is reduced or when insulin resistance occurs, this can result in elevated levels of glucose in the bloodstream, a condition that can lead to serious health problems. On the other hand, the production of glucose refers to the physiological procedure where the liver converts stored glycogen, a form of glucose storage, into glucose before it is released into the bloodstream. This process is essential for maintaining the body’s energy balance. However, research has shown that THCV can suppress this process by inhibiting the action of the enzyme called glucose-6-phosphatase, which plays a key role in the conversion of glycogen to glucose. The suppression of glucose production by THCV thus contributes to its beneficial effects on glucose regulation. The influence of THCV on both insulin sensitivity and glucose production, as revealed in these studies, strongly suggest its potential as an effective treatment option for type 2 diabetes, a chronic condition that affects millions of people worldwide. This potential is further bolstered by the empirical evidence derived from various animal studies examining the impacts of THCV on glucose regulation. For instance, in one experimental study conducted on obese mice, it was found that treatment with THCV led to an increase in insulin sensitivity and a decrease in fasting blood glucose levels. This suggests a possible therapeutic role for THCV in managing obesity-related insulin resistance and hyperglycemia. In another study conducted on rats with type 2 diabetes, THCV treatment resulted in enhanced glucose tolerance and amplified insulin secretion, indicating its potential to improve pancreatic function and glucose metabolism. Furthermore, research on diabetic dogs showed that treatment with THCV decreased fasting blood glucose levels and improved glucose tolerance. This is an important finding as it suggests that THCV could be beneficial not just in managing human diabetes, but also in treating diabetes in veterinary medicine. While the promising results derived from these animal studies certainly warrant further investigation in human trials, the potential of THCV as a breakthrough therapeutic avenue for type 2 diabetes is undeniable. If these effects can be replicated in human studies, it could revolutionize the current approach to managing this widespread condition, offering hope to millions of people around the world. It underscores the importance of continued research in this area, as we strive to understand the full potential of THCV and other similar compounds in treating chronic conditions like type 2 diabetes.

According to [Cannabis and Diabetes](^1^), THCV is one of the cannabinoids that has been shown to have benefits for blood sugar control and metabolism in diabetes studies. It also states that cannabis can help with other aspects of diabetes, such as reducing inflammation, lowering blood pressure, relieving neuropathic pain, and improving circulation¹.

Another article, [THCV: A Fascinating Cannabinoid That Helps Prevent Type 2 Diabetes](^2^), explains how THCV can increase insulin sensitivity and improve glucose tolerance without altering plasma lipids. It also mentions that THCV can act as an appetite suppressant, which could help with weight management².

A third article, [THCV and Diabetes: Is There a Link?](^3^), summarizes the findings of the animal studies that you mentioned, and also discusses the possible mechanisms of action of THCV on the endocannabinoid system and the CB1 and CB2 receptors. It also notes that THCV has a high safety profile and low psychoactivity³.

Finally, an article titled [Effects of the Cannabinoid THCV on Diabetes](^4^) provides more details on the clinical trials that have been conducted on THCV and diabetes. It reports that low-dose THCV, acting as an antagonist of the CB1 receptor, can decrease blood glucose levels and increase insulin production in people with type 2 diabetes. It also suggests that THCV could be used alone or in combination with existing treatments⁴.

(1) Cannabis and Diabetes. https://www.diabetes.co.uk/recreational-drugs/cannabis.html.

(2) Cannabis and Diabetes. https://www.diabetes.co.uk/recreational-drugs/cannabis.html.

(3) Cannabinoid THCV Helps Prevent Type 2 Diabetes – The Cannabis Advisory. https://www.thecannabisadvisory.com/cannabis-news/thcv-cannabinoid-type-2-diabetes/.

(4) Cannabinoid THCV Helps Prevent Type 2 Diabetes – The Cannabis Advisory. https://www.thecannabisadvisory.com/cannabis-news/thcv-cannabinoid-type-2-diabetes/.

(5) THCv and Diabetes: Is There a Link? – Extraction Magazine. https://extractionmagazine.com/2020/05/16/thcv-and-diabetes-is-there-a-link/.

(6) THCv and Diabetes: Is There a Link? – Extraction Magazine. https://extractionmagazine.com/2020/05/16/thcv-and-diabetes-is-there-a-link/.

(7) Effects of the Cannabinoid THCV on Diabetes | THCV and Diabetes …. https://naturesbreakthrough.com/blogs/news/effects-of-the-cannabinoid-thcv-on-diabetes.

(8) Effects of the Cannabinoid THCV on Diabetes | THCV and Diabetes …. https://naturesbreakthrough.com/blogs/news/effects-of-the-cannabinoid-thcv-on-diabetes.